Abstract
After a promising preliminary report by Olweny et al. was published in 1975 [1], doxorubicin came into use and was considered the most reliable anticancer agent for hepatocellular carcinoma (HCC). However, in recent well-controlled Phase 11 trials which included doxorubicin, it was demonstrated that no active anticancer agent for HCC shows more than a 15% response rate reproducibly [2].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
Similar content being viewed by others
References
Olweny CLM, Toya T, Katongole-Mbidde E, Mugerwa J, Kyalwazi SK, Cohen H (1975) Treatment of hepatocellular carcinoma with adriamycin. Preliminary communication. Cancer 36: 1250–1257
Falkson G, Coetzer B (1987) Chemotherapy of primary liver cancer. In: Okuda K, Ishak KJ (eds) Neoplasms of the liver. Springer-Verlag, Tokyo, pp 331–326
Okamoto E, Yamanaka N, Toyosaka Y, Tanaka N, Yabuki K (1987) Current status of hepatic resection in the treatment of hepatocellular car cinoma. In: Okuda K, Ishak KJ (eds) Neoplasms of the liver. Springer-Verlag, Tokyo, pp 353–363
Okuda K, Ohtsuki T, Obata H, Tominatsu M, Okazaki N, Hasegawa H, Nakajima Y, Ohnishi K (1985) Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56: 918–928
Einhorn LH (1981) Testicular cancer as a model for a curable neoplasm: The Richard and Hinda Rosenthal Foundation Award Lecture. Cancer Res 41: 3275–3280
Yamasaki S, Hasegawa H, Makuuchi M (1981) Clinicopathological observation of minute liver cancer and the new method of hepatectomy. An Analysis of 27 cases. Acta Hepatol Jpn 22: 1714–1724
Ebara M, Ohto M, Sugiura N, Kita K, Yoshikawa M, Okuda K, Kondo F, Kondo Y (1990) Percutaneous ethanol injection for the treatment of small hepatocellular carcinoma. Study of 95 patients. J Gastroenterol Hepatol 5: 616–626
Yamada R, Sato M, Kawabata T, Nakatsuka H, Nakamura K, Takashima S (1983) Hepatic artery embolization in 120 patients with unresectable hepatoma. Radiology 148: 397–401
The Liver Study Group of Japan (1990) Primary liver cancer in Japan (ninth report)
WHO (1979) WHO handbook for reporting results of cancer treatment, WHO Offset Publication, No. 48
Oken MM, Greech RH, Horton J, Davis TE, McFadden Carbone PP (1982) Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649–655
Okazaki N, Yoshida T, Yoshino M, Okada S, Shimada Y, Moriyama N, Takayasu K (1991) Changes in mode of response to chemotherapy for hepatocellular carcinoma induced by transarterial embolization. A case report. Jpn J Clin Oncol 21: 69–67
Okada S, Okazaki N, Nose H, Ohkura H, Sugano K, Aoki K (to be published) (1992) Evaluation of chemotherapeutic effects for hepatocellular carcinoma based on survival analysis. Acta Hepatol Jpn
Okazaki N, Yoshino M, Yoshida T, Hizikata A, Hasegawa H (1986) Systemic chemotherapy of hepatocellular carcinoma. Jpn J Cancer Chemother 13: 584–1588
Okazaki N, Yoshino M, Yoshida T, Hijikata A (1985) A controlled study of intravenous doxorubicin versus oral tegafur in patients with hepatocellular carcinoma. J Jpn Soc Cancer Ther 20: 556–561
Tokyo Liver Cancer Chemotherapy Study Group (1985) Phase II study of co-administration of uracil and tegafur (UFT) in hepatocellular carcinoma. Jpn J Clin Oncol 15: 559–562
Yoshino M, Okazaki N, Yoshida T, Kanda Y, Miki M, Oda H, Sasagawa Y, Hayashi S, Hoshimoto N (1989) A phase II study of etoposide in patients with hepatocellular carcinoma by Tokyo Liver Cancer Chemotherapy Study group. Jpn J Clin Oncol 19: 120–122
Yoshida T, Okazaki N, Yoshino M, Ohkura H, Miyamoto K, Shimada Y (1988) Phase II trial of mitoxantrone in patients with hepatocellular carcinoma. Eur J Cancer Clin Oncol 124: 1897–1898
Yoshida T, Okazaki N, Yoshino M, Ohkura H, Shimada Y (1990) Phase II trial of high dose recombinant gamma-interferon in advanced hepatocellular carcinoma. Eur J Cancer 26: 545–546
Okada S, Okazaki N, Nose H, Aoki K, Simada Y (to be published) (1992) Phase II trial of cisplatin for hepatocellular carcinoma. Eur J Cancer
Olweny CLM, Katongole-Mbidde E, Bahendeka S, Otim D, Mugerwa J, Kyalwazi SK (1980) Further experiences in treating patients with hepatocellular carcinoma in Uganda. Cancer 46: 2717–2722
Chlebowski RT, Brzechwa-Adjukiewicz A, Cowden A, Block JB, Tong M, Chan KK (1984) Doxorubicin (75mg/m2) for hepatocellular carcinoma: Clinical and pharmacokinetic results. Cancer Treat Rep 68: 487–491
Falkson G, Maclntyre JM, Moertel CG, Johnson LA, Scherman RC (1984) Primary liver cancer: An Eastan Cooperative Oncology Group Trial. Cancer 54: 970–977
Lai CL, Wu PC, Chan GCB, Lok ASF, Lin HJ (1988) Doxorubicin verus no antitumor therapy in inoperable hepatocellular carcinoma. A prospective randomized trial. Cancer 62: 479–483
Höchster HS, Green MD, Speyer J, Fazzini E, Blum R, Muggia FM (1985) The efficacy of high-dose 4’Epirubicin ( Epirubicin ): Activity in hepatocellular carcinoma. J Clin Oncol 3: 1535–1540
Shiu W, Leung N, Li M, Leug WT, Li AKG (1988) The efficacy of high-dose 4’Epidoxorubicin in hepatocellular carcinoma. Jpn J Clin Oncol 18: 235–237
Davis RB, Van Echo DA, Leone LA, Henderson ES (1986) Phase II trial of mitoxantrone in advanced primary liver cancer. A Cancer Leukemia Group B Study. Cancer Treat Rep 70: 1125–1126
Falkson G, Ryan LM, Johnson LA, Simson IW, Coetzer BJ, Carbone PP, Creech RH, Schutt AJ (1987) A random phase II study of mitoxantrone and cisplatin in patients with hepatocellular carcinoma. An ECOG study. Cancer 60: 2141–2145
Ohya T, Kikuchi S, Kato K, Takei T, Takeichi M, Nakano S, Watahiki M, Koyama T, Yamamoto M, Komatsu T, Miwa N, Kasugai T, Hisano N, Tuboi Y, Kikuchi S, Tomusa A (1982) Clinical studies of chemotherapy for primary hepatocellular carcinoma. Jpn J Cancer Chemother 9: 1623–1627
Cavalli F, Rozencweig M, Renard J, Goldhirsch A, Hansen HH (1981) Phase II study of oral VP-16-213 in hepatocellular carcinoma. Eur J Cancer Clin Oncol 17: 1079–1082
Shiu W, Mok SD, Leung N, Li M, Zacharia A, Li A, Martin C (1987) Phase 2 study of high dose etoposide (VP16-213) in hepatocellular carcinoma. Jpn J Clin Oncol 17: 113–115
Ravry MJR, Omura GA, Bartolucii AA, Einhorn L, Kramer B, Davila E (1986) Phase II evaluation of cisplatin in advanced hepatocellular carcinoma and cholangiocarcinoma: A Southern Cancer Study Group Trial. Cancer Treat Rep 70: 311–312
Okazaki N, Yoshino M, Yoshida T (1989) Chemotherapy for hepatocellular carcinoma. Kan Tan Sui 18: 239–242
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1992 Springer-Verlag Tokyo
About this chapter
Cite this chapter
Okazaki, N., Okada, S., Nose, H., Aoki, K. (1992). Systemic chemotherapy for hepatocellular carcinoma. In: Tobe, T., et al. Primary Liver Cancer in Japan. Springer, Tokyo. https://doi.org/10.1007/978-4-431-68177-9_29
Download citation
DOI: https://doi.org/10.1007/978-4-431-68177-9_29
Publisher Name: Springer, Tokyo
Print ISBN: 978-4-431-68179-3
Online ISBN: 978-4-431-68177-9
eBook Packages: Springer Book Archive